
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)
July 27, 2018

Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34899
(Commission
File Number)

16-1590339
(IRS Employer
Identification No.)

1305 O'Brien Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)

(650) 521-8000
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(d)

On July 27, 2018, the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) appointed Christian O. Henry, age 50, as a Class I director to serve on the Board effective immediately and as such, he will be up for election in 2020 to serve an additional three years.

Mr. Henry served as Executive Vice President & Chief Commercial Officer of Illumina, Inc. from 2015 through January 2017, and previously served as Senior Vice President & Chief Commercial Officer from 2014 to 2015, Senior Vice President & General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial Officer & General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development & Chief Financial Officer from 2009 to 2010, Senior Vice President & Chief Financial Officer from 2007 to 2009, and Vice President & Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr. Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr. Henry served as Vice President, Finance & Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr. Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr. Henry served as General Accounting Manager of Sugen, Inc. Mr. Henry began his career in 1992 at Ernst & Young LLP, where he was a Senior Accountant through 1996. Mr. Henry currently serves as a director and chairman of the board of WAVE Life Sciences Ltd. Mr. Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine.

There are no arrangements or understandings between Mr. Henry and any other person pursuant to which he was appointed as a director, nor are there any transactions between Mr. Henry and the Company that would be reportable under Item 404(a) of Regulation S-K promulgated by the SEC.

Pursuant to the Company’s outside director compensation policy, as disclosed in the Company’s proxy statement for the 2018 Annual Meeting of Stockholders, as a non-employee director, Mr. Henry will receive an annual retainer of \$35,000. Pursuant to the Company’s outside director equity compensation policy, Mr. Henry was automatically granted a stock option to purchase 35,000 shares of the Company’s common stock on the date of his appointment to the Board. Mr. Henry will also execute the Company’s standard form of indemnification agreement.

ITEM 7.01. REGULATION FD DISCLOSURE.

On July 31, 2018, the Company issued a press release announcing the appointment of Mr. Henry to the Board. A copy of the press release is included as Exhibit 99.1.

This information is intended to be furnished under Item 7.01 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated July 31, 2018.

Pacific Biosciences Appoints Christian Henry to Board of Directors
Industry Veteran Previous Served as EVP & Chief Commercial Officer of Illumina

MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it has appointed industry veteran Christian Henry to its Board of Directors. Mr. Henry has over 20 years of leadership experience, including over 10 years in executive-level positions at Illumina, Inc.

Mr. Henry joined Illumina in 2005 and, during his tenure there, he served in multiple executive roles, including Vice President & Chief Financial Officer, Senior Vice President, Corporate Development, General Manager Life Sciences, and General Manager Genomics Solutions. In his most recent position as Executive Vice President & Chief Commercial Officer, Mr. Henry had direct responsibility for the development and implementation of all aspects of Illumina's commercial strategy. Mr. Henry also played leading roles in Illumina's acquisitions of several life sciences companies, and led Illumina's successful integration of Solexa.

Henry was awarded CFO of the Year by the San Diego Business Journal in 2008 and 2009. He received his BA in biochemistry and cell biology from the University of California, San Diego and his MBA from the University of California, Irvine. Mr. Henry currently serves as chairman of the board of WAVE Life Sciences Ltd., and also serves on the board of Gingko Bioworks, Inc.

"Christian is a highly-respected executive and industry veteran and we are delighted to have him join our Board of Directors," said Michael Hunkapiller, Chairman and Chief Executive Officer of Pacific Biosciences. "His business expertise, scientific background and deep understanding of the sequencing market will be a valuable addition to PacBio as our products become more widely established for a broad spectrum of applications, including highly accurate and contiguous *de novo* genome assembly, transcript isoform annotation and, particularly with the launch of our new SMRT® Cell 8M next year, larger scale use of our technology in population-scale human genome projects and clinical research."

"I am very pleased to join PacBio's board at this exciting time for the company," said Christian Henry. "I am enthusiastic about its truly unique SMRT Sequencing technology and potential to become an increasingly significant player in the global sequencing market, and I look forward to working with the company's board and management team to drive greater adoption for PacBio's current and upcoming products."

Bill Ericson, Lead Independent Director of Pacific Biosciences, Managing Partner at Mohr Davidow Ventures and founding partner at Wildcat Venture Partners, commented: "Christian brings with him a wealth of relevant experience and domain expertise. As a key member of the management team that built Illumina into the sequencing market leader that it is today, his perspective and guidance will be invaluable as PacBio scales its commercial operations and seeks to further expand its market presence."

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences' products enable: *de novo* genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences' technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and

software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future product launches, markets or market adoption, availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, the suitability or utility of products or technologies for particular applications or projects, the expected benefits of appointing Mr. Henry as a company director and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences' control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences' most recent filings with the Securities and Exchange Commission, including Pacific Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors."

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Media:

Nicole Litchfield

415.793.6468

nicole@bioscribe.com

Investors:

Trevin Rard

650.521.8450

ir@pacificbiosciences.com
